Cabaletta Bio, Inc. · NASDAQ:CABA
Cabaletta Bio — Investor Presentation (October 2023)
25 slides from Cabaletta Bio's investor presentation, Oct 2, 2023
Slide 1: Corporate Presentation October 2023
Exhibit 99.1 Corporate Presentation OCTOBER 2023 © 2023 Cabaletta Bio. All rights reserved.
Slide 2: Disclaimer
Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection wi
Slide 3: Develop and launch the first curative targeted cellular therapies for autoimmune diseases
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases 3 3
Slide 4: Pursuing cures for a broad range of autoimmune diseases
® Cabaletta : Pursuing cures for a broad range of autoimmune diseases Leveraging years of experience with cellular therapy in autoimmunity to initiate CABA-201 clinical trials CARTA Strategy | CABA-201 (4-1BB CD19-CAR T) to be evaluated in parallel myositis, SLE & SSc Phase 1/2 studies Advancing myo
Slide 5: One CABA platform, two strategies to address autoimmune diseases
One CABA™ platform, two strategies to address autoimmune diseases Complementary strategies to optimize clinical outcomes using cellular therapies in autoimmune diseases CARTA CAART Chimeric Antigen Receptor T cells for Autoimmunity Chimeric AutoAntibody Receptor T cells Potential to ‘reset the immun
Slide 6: CABA platform may apply across a range of autoimmune diseases
CABA™ platform may apply across a range of autoimmune diseases Biologic opportunity for cure or treatment may be possible in dozens of autoimmune diseases* 1,2,3,5 • Myasthenia Gravis Neurology 6 • Multiple Sclerosis 3,4,5,6 • Systemic Lupus Erythematosus 3 • Neuromyelitis Optica • Idiopathic inflam
Slide 7: Pipeline targeting autoimmune diseases where cure is possible
Pipeline targeting autoimmune diseases where cure is possible Discovery Phase 1/2 Phase 2/3 CABA™ Platform Indication Program Preclinical Dermatomyositis Myositis (IIM, Idiopathic Anti-Synthetase IND cleared Inflammatory Syndrome 1 Myopathy) Immune-Mediated Necrotizing Myopathy CARTA Lupus Nephritis
Slide 8: CABA-201: Chimeric Antigen Receptor T Cells for Autoimmunity
Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201 8
Slide 9: Academic data: Immune system reset in autoimmune patients
Academic data: Immune system reset in autoimmune patients Promising clinical responses observed across several autoimmune diseases in academic CD19-CAR T trials Emerging clinical data with 2 5 8 SLE (N=5) Myositis (N=1) Systemic sclerosis (N=1) Robust improvement 1 4-1BB CD19-CAR T in… in clinical d
Slide 10: CABA-201: CD19-targeting CAR T therapy for autoimmune diseases
CABA-201 CABA-201: CD19-targeting CAR T therapy for autoimmune diseases 1,2 3,4 Cabaletta’s CD19 binder with similar in vitro & in vivo activity to FMC63 (binder used in academic studies ) CABA-201 Clinical data reported by IASO using 1 Similar in vitro & in vivo biologic activity to FMC63 5 license
Slide 11: CABA-201 Myositis: Strong scientific rationale & significant disease burden
CABA-201 Myositis: Strong scientific rationale & significant disease burden ~66K U.S. patients with IIM subtypes with B cell involvement; frequently severe, with limited treatment options Potential manifestations & subtype prevalence Autoimmune disease with B cell involvement 1 Key myositis subtypes
Slide 12: Phase 1/2 study design for CABA-201 in patients with myositis
CABA-201 Phase 1/2 study design for CABA-201 in patients with myositis CABA-201 to be evaluated in patients with active myositis, including DM, ASyS & IMNM Study Endpoint & Objectives Phase 1/2 Study of CABA-201 Primary objective: Evaluate safety & tolerability of CABA-201 in subjects with Open labe
Slide 13: SLE & Lupus Nephritis: High unmet clinical need
CABA-201 SLE & Lupus Nephritis: High unmet clinical need ~320,000 SLE patients in the U.S., ~40% with LN, who face increased risk of kidney failure & death Potential SLE Manifestations SLE is a chronic autoimmune Skin & Lupus nephritis (LN) is a 1 mucosa disease that affects ~160-320K serious compli
Slide 14: Phase 1/2 study design for CABA-201 in patients with SLE
CABA-201 Fast Track Phase 1/2 study design for CABA-201 in patients with SLE Designation CABA-201 to be evaluated in patients with active SLE with or without renal involvement Study Endpoint & Objectives Phase 1/2 Study of CABA-201 Primary objective: Evaluate safety & tolerability of CABA-201 in sub
Slide 15: Systemic Sclerosis: Profound unmet need & limited options
CABA-201 Systemic Sclerosis (SSc): Profound unmet need & limited options 1,2 ~88K SSc patients in the U.S., with intractable progression leading to chronic morbidity & high mortality 2 1 Rare, potentially fatal, chronic disease Potential manifestations & classification • Typically, middle age onset
Slide 16: Phase 1/2 study design for CABA-201 in patients with SSc
CABA-201 Fast Track Phase 1/2 study design for CABA-201 in patients with SSc Designation CABA-201 to be evaluated in patients with systemic sclerosis with severe skin or organ involvement Study Endpoint & Objectives Phase 1/2 Study of CABA-201 Open label trial to evaluate CABA-201 in subjects with P
Slide 17: Accelerating development of CABA-201 for autoimmune diseases
CABA-201 Accelerating development of CABA-201 for autoimmune diseases Our product candidate & uniquely experienced people inform our differentiated development path Efficient clinical trial designs for CABA-201 facilitate rapid & broad development program Candidate with 4-1BB co-stim domain & simila
Slide 18: Chimeric AutoAntibody Receptor T Cells: DSG3-CAART & MuSK-CAART
Chimeric AutoAntibody Receptor T Cells DSG3-CAART & MuSK-CAART 18
Slide 19: DSG3-CAART: Ongoing DesCAARTes study in mucosal PV
DSG3-CAART Fast Track Fast Track Orphan Drug Ongoing DesCAARTes™ study in patients with mucosal PV Designation Designation Designation Enrolling in Flu / Cy / IVIg cohort to evaluate ability to improve engraftment & clinical activity ™ 1 Antibody-mediated disease DesCAARTes study of DSG3-CAART • Muc
Slide 20: MuSK-CAART: Ongoing MusCAARTes study in MuSK+ MG
MuSK-CAART Fast Track Orphan Drug Ongoing MusCAARTes™ study in patients MuSK+ MG Designation Designation Additional opportunity to evaluate CAART platform in disease with differentiated biology ™ MusCAARTes study of MuSK-CAART 1 Compelling biologic rationale, similar to PV Ongoing open-label study t
Slide 21: Corporate Summary
Corporate Summary Cabaletta Bio”
Slide 22: Manufacturing strategy
Manufacturing strategy Three-stage approach allows for efficient allocation of capital while leveraging experienced partners Stage 1: Stage 2: Stage 3: Penn CDMOs & CABA Process Commercialization & Scale-Up Data-gated, staged investment 2019 – 2021 – • Cell processing capacity secured • CDMOs for ve
Slide 23: Cabaletta Bio leadership
Cabaletta Bio leadership LEADERSHIP TEAM Steven Nichtberger, M.D. Samik Basu, M.D. Gwendolyn Binder, Ph.D. David J. Chang, M.D., M.P.H., FACR Arun Das, M.D. President, CEO & Chairman Chief Scientific Officer President, Science & Technology Chief Medical Officer Chief Business Officer Michael Gerard
Slide 24: Pursuing cures for a broad range of autoimmune diseases
® Cabaletta : Pursuing cures for a broad range of autoimmune diseases Leveraging years of experience with cellular therapy in autoimmunity to initiate CABA-201 clinical trials CARTA Strategy | CABA-201 (4-1BB CD19-CAR T) to be evaluated in parallel myositis, SLE & SSc Phase 1/2 studies Advancing myo
Slide 25: © 2023 Cabaletta Bio. All rights reserved.
Corporate Presentation OCTOBER 2023 © 2023 Cabaletta Bio. All rights reserved.